1. Home
  2. SYRE vs HII Comparison

SYRE vs HII Comparison

Compare SYRE & HII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

SELL

Current Price

$96.64

Market Cap

8.7B

Sector

Health Care

ML Signal

SELL

Logo Huntington Ingalls Industries Inc.

HII

Huntington Ingalls Industries Inc.

HOLD

Current Price

$289.44

Market Cap

10.1B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
SYRE
HII
Founded
2013
1886
Country
United States
United States
Employees
N/A
44000
Industry
Biotechnology: Pharmaceutical Preparations
Marine Transportation
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
8.7B
10.1B
IPO Year
2015
2010

Fundamental Metrics

Financial Performance
Metric
SYRE
HII
Price
$96.64
$289.44
Analyst Decision
Strong Buy
Buy
Analyst Count
18
12
Target Price
$122.53
★ $362.58
AVG Volume (30 Days)
★ 1.1M
570.9K
Earning Date
11-03-2026
10-29-2026
Dividend Yield
N/A
★ 1.85%
EPS Growth
N/A
★ 10.24
EPS
N/A
★ 14.53
Revenue
N/A
★ $12,484,000,000.00
Revenue This Year
N/A
$8.01
Revenue Next Year
N/A
$6.98
P/E Ratio
★ N/A
$20.92
Revenue Growth
N/A
★ 8.23
52 Week Low
$21.15
$255.36
52 Week High
$110.18
$460.00

Technical Indicators

Market Signals
Indicator
SYRE
HII
Relative Strength Index (RSI) 60.94 62.06
Support Level $93.45 $281.35
Resistance Level $105.09 $337.15
Average True Range (ATR) 4.29 9.20
MACD 1.22 4.70
Stochastic Oscillator 93.81 60.84

Price Performance

Historical Comparison
SYRE
HII

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

About HII Huntington Ingalls Industries Inc.

Huntington Ingalls Industries is the largest independent military shipbuilder in the US, spun out from Northrop Grumman in 2011. It operates three segments, two of which are storied shipyards: Ingalls produces non-nuclear-powered ships, including amphibious landing ships and Arleigh Burke-class destroyers, while Newport News produces nuclear-powered ships as the only producer of Gerald Ford-class aircraft carriers and a major subcontractor on Virginia- and Columbia-class nuclear submarines. HII shares production of destroyers and nuclear submarines with General Dynamics' Bath Iron Works and Electric Boat shipyards, respectively. The company's mission technologies segment produces uncrewed sea vessels and provides a range of IT and other services to US government agencies.

Share on Social Networks: